文献速递流行病学与生物统计真实世界研究与卫生经济

1990-2021年204个国家和地区及811个次国家级地区288种死因的全球疾病负担与预期寿命分解:2021年全球疾病负担研究的系统分析

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
PubMed 文献 · Lancet · 2024-04-03

全球疾病负担研究2021对1990至2021年204个国家和地区及811个次国家级地区288种死因的死亡率和寿命损失年进行估计,使用56604个数据源和死因集成模型。2021年COVID-19取代卒中成为第二位的年龄标化死因,每10万人口94.0例死亡(95%UI 89.2-100.0);2019至2021年全球预期寿命净减少1.6年,主要因COVID-19和其他大流行相关死亡率上升。

要点

  • 2019年与1990年全球年龄标化死因前四位相同:缺血性心脏病、卒中、慢性阻塞性肺疾病和下呼吸道感染。
  • 2021年COVID-19取代卒中成为第二位年龄标化死因,每10万人口94.0例死亡(95%UI 89.2-100.0)。
  • 2019至2021年全球预期寿命净减少1.6年,主要因COVID-19和其他大流行相关死亡率升高。

核心结论

  • COVID-19大流行打断了预期寿命的长期改善和许多主要死因死亡率的下降,其不良影响在不同人群间分布不均。
  • 尽管有大流行,研究期间在应对若干显著死因方面仍持续取得进展,全球预期寿命整体改善。
  • 七个GBD超级区域在1990至2021年间均显示整体改善,掩盖了大流行期间的负面影响。
  • 若干曾经全球广泛存在的死因如今在地理上日益集中,分析死亡集中模式可能揭示已成功实施公共卫生干预的领域。

研究设计与样本

  • GBD 2021死因分析估计1990至2021年每年204个国家和地区及811个次国家级地区288种死因按年龄-性别-地点-年份的死亡率和寿命损失年。
  • 分析使用56604个数据源,包括生命登记、口头尸检以及调查、普查、监测系统和癌症登记等。
  • 多数死因的年龄别死亡率使用死因集成模型估计,该工具评估不同统计模型和协变量排列的样本外预测效度并合并结果。
  • 寿命损失年按每种死因-年龄-性别-地点-年份的死亡数与各年龄标准预期寿命的乘积计算。
  • 不确定性区间由每个指标1000次抽样分布的第2.5和第97.5百分位数生成。

主要发现

  • 2019年全球年龄标化死因前四位与1990年相同,依次为缺血性心脏病、卒中、慢性阻塞性肺疾病和下呼吸道感染。
  • 2021年COVID-19取代卒中成为第二位年龄标化死因,每10万人口94.0例死亡(95%UI 89.2-100.0)。
  • 2021年COVID-19年龄标化死亡率最高的是撒哈拉以南非洲(每10万人口271.0例死亡,95%UI 250.1-290.7)和拉丁美洲及加勒比(195.4例,95%UI 182.1-211.4)。
  • 2021年COVID-19年龄标化死亡率最低的是高收入超级区域(每10万人口48.1例死亡,95%UI 47.4-48.8)和东南亚、东亚及大洋洲(23.2例,95%UI 16.3-37.2)。
  • 2019至2021年全球预期寿命净减少1.6年,主要因COVID-19和其他大流行相关死亡率升高。

关键数值与推荐

  • 2021年COVID-19年龄标化死亡率为每10万人口94.0例(95%UI 89.2-100.0),取代卒中成为第二位年龄标化死因。
  • 2019至2021年全球预期寿命净减少1.6年。
  • 研究期间东南亚、东亚及大洋洲预期寿命总体增加8.3年(95%UI 6.7-9.9),因COVID-19的预期寿命减少最小(0.4年)。
  • 拉丁美洲及加勒比因COVID-19的预期寿命减少最大(3.6年)。
  • 截至2021年,288种死因中有53种高度集中在不到全球人口50%的地点,1990年仅有44种呈现此模式。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为,关于死因驱动预期寿命增加的地区差异的发现具有明确政策效用。
  • 作者认为,将成功公共卫生干预转化到某些死因仍顽固存在的地点,可为改善各地人群预期寿命的政策提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS: The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION: Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024. PMID: 38582094. doi:10.1016/S0140-6736(24)00367-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。